Reference is made to the stock exchange notice dated 14 August 2017, whereby it was informed that Tor Erik Andersen had resigned from the position as CEO of the Company and Roger Hofseth had assumed the position as CEO.

 

As a consequence of this, the board of directors (the "Board") of Hofseth BioCare ASA ("HBC" or the "Company") has today accepted Roger Hofseth's resignation as chairman of the Board. Deputy director Ola Holen will function as the chairman of the Board until a new chairman of the Board may be elected.

 

The Board is very satisfied that Mr. Holen, with his broad experience from the fish processing industry, will function as interim chairman going forward.

 

For further information, please contact:

Roger Hofseth, CEO of Hofseth BioCare ASA
Mob: +47 95147941
E-mail: rh@hofseth-as.no

 

Jon Olav Ødegård, CFO of Hofseth BioCare ASA
Mob: +47 93632966
E-mail: joo@hofsethbiocare.no

 

About Hofseth BioCare ASA:

HBC is a Norwegian biotech company that offers high-value ingredients and finished products for humans and pets. The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, HBC is able to preserve the quality of salmon oil, proteins and calcium, prepared of fresh salmon off-cuts. HBC's objective is to contribute to the efficient use of marine resources and deliver quality products for ingredients and finished consumer products in the nutrition market. Hofseth BioCare's headquarters are located in Ålesund, Norway with branches in Oslo, Chicago, Mumbai and Tokyo. HBC is listed on Oslo Stock Exchange Axess list with ticker "HBC". More information about Hofseth BioCare at www.hofsethbiocare.com and www.facebook.com/hofsethbiocare

 

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.